Please call Clinical Labs of Hawaii at 808.677.7998 (Option 1) with questions about this test.
Synonyms
Beta-HCG levels
Beta-HCG serum concentration
Beta-HCG, serum
human chorioinic gonadotropin, serum
Beta-hCG , Quantitative (Tumor Marker)
Collect
Serum separator tube. Also acceptable: Lavender (K2EDTA or K3EDTA), pink (K2EDTA), or green (lithium heparin).
Specimen Preparation
Allow specimen to clot completely at room temperature. Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.4 mL)
Stability (from collection to initiation)
After separation from cells: Ambient: 5 days; Refrigerated: 2 weeks; Frozen: 1 year
Unacceptable Conditions
CSF (refer to Beta-hCG, Quantitative (Tumor Marker) CSF, ARUP test code 0020730). Specimens left to clot at 2-8°C or specimens subjected to repeated freeze/thaw cycles.
Storage/Transport Temperature
Refrigerated.
Performed
Sun-Sat
Reported
Within 24 hours
Methodology
Quantitative Electrochemiluminescent Immunoassay
Test Site
ARUP (70029)
Reference Interval
Male: 0-3 IU/L Female: 0-5 IU/L
Interpretive Data
Interpretive Data: Human chorionic gonadotropin (hCG) is a valuable aid in the management of patients with trophoblastic tumors, nonseminomatous testicular tumors, and seminomas when used in conjunction with information available from the clinical evaluation and other diagnostic procedures. Increased serum hCG concentrations have also been observed in melanoma, carcinomas of the breast, gastrointestinal tract, lung, and ovaries, and in benign conditions, including cirrhosis, duodenal ulcer, and inflammatory bowel disease. This result cannot be interpreted as absolute evidence of the presence or absence of malignant disease. This result is not interpretable as a tumor marker in pregnant females.
The combination of the specific monoclonal antibodies used in the Roche Beta HCG electrochemiluminescent immunoassay recognize the holo-hormone, "nicked" forms of hCG, the beta-core fragment, and the free beta-subunit. Results obtained with different test methods or kits cannot be used interchangeably. Although this assay is FDA cleared for use in the detection of pregnancy, it is not labeled for use as a tumor marker.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
CPT Codes
84702
LOINC
21198-7
Collect
Serum separator tube. Also acceptable: Lavender (K2EDTA or K3EDTA), pink (K2EDTA), or green (lithium heparin).
Specimen Preparation
Allow specimen to clot completely at room temperature. Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.4 mL)
Storage/Transport Temperature
Refrigerated.
Stability (from collection to initiation)
After separation from cells: Ambient: 5 days; Refrigerated: 2 weeks; Frozen: 1 year
Interpretive Data
Interpretive Data: Human chorionic gonadotropin (hCG) is a valuable aid in the management of patients with trophoblastic tumors, nonseminomatous testicular tumors, and seminomas when used in conjunction with information available from the clinical evaluation and other diagnostic procedures. Increased serum hCG concentrations have also been observed in melanoma, carcinomas of the breast, gastrointestinal tract, lung, and ovaries, and in benign conditions, including cirrhosis, duodenal ulcer, and inflammatory bowel disease. This result cannot be interpreted as absolute evidence of the presence or absence of malignant disease. This result is not interpretable as a tumor marker in pregnant females.
The combination of the specific monoclonal antibodies used in the Roche Beta HCG electrochemiluminescent immunoassay recognize the holo-hormone, "nicked" forms of hCG, the beta-core fragment, and the free beta-subunit. Results obtained with different test methods or kits cannot be used interchangeably. Although this assay is FDA cleared for use in the detection of pregnancy, it is not labeled for use as a tumor marker.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Unacceptable Conditions
CSF (refer to Beta-hCG, Quantitative (Tumor Marker) CSF, ARUP test code 0020730). Specimens left to clot at 2-8°C or specimens subjected to repeated freeze/thaw cycles.
Please call Clinical Labs of Hawaii at 808.677.7998 (Option 1) with questions about this test.
Synonyms
Beta-HCG levels
Beta-HCG serum concentration
Beta-HCG, serum
human chorioinic gonadotropin, serum
Beta-hCG , Quantitative (Tumor Marker)
Collect
Serum separator tube. Also acceptable: Lavender (K2EDTA or K3EDTA), pink (K2EDTA), or green (lithium heparin).
Specimen Preparation
Allow specimen to clot completely at room temperature. Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.4 mL)
Stability (from collection to initiation)
After separation from cells: Ambient: 5 days; Refrigerated: 2 weeks; Frozen: 1 year
Unacceptable Conditions
CSF (refer to Beta-hCG, Quantitative (Tumor Marker) CSF, ARUP test code 0020730). Specimens left to clot at 2-8°C or specimens subjected to repeated freeze/thaw cycles.
Storage/Transport Temperature
Refrigerated.
Performed
Sun-Sat
Reported
Within 24 hours
Methodology
Quantitative Electrochemiluminescent Immunoassay
Test Site
ARUP (70029)
Reference Interval
Male: 0-3 IU/L Female: 0-5 IU/L
Interpretive Data
Interpretive Data: Human chorionic gonadotropin (hCG) is a valuable aid in the management of patients with trophoblastic tumors, nonseminomatous testicular tumors, and seminomas when used in conjunction with information available from the clinical evaluation and other diagnostic procedures. Increased serum hCG concentrations have also been observed in melanoma, carcinomas of the breast, gastrointestinal tract, lung, and ovaries, and in benign conditions, including cirrhosis, duodenal ulcer, and inflammatory bowel disease. This result cannot be interpreted as absolute evidence of the presence or absence of malignant disease. This result is not interpretable as a tumor marker in pregnant females.
The combination of the specific monoclonal antibodies used in the Roche Beta HCG electrochemiluminescent immunoassay recognize the holo-hormone, "nicked" forms of hCG, the beta-core fragment, and the free beta-subunit. Results obtained with different test methods or kits cannot be used interchangeably. Although this assay is FDA cleared for use in the detection of pregnancy, it is not labeled for use as a tumor marker.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
CPT Codes
84702
LOINC
21198-7
Collection
Collect
Serum separator tube. Also acceptable: Lavender (K2EDTA or K3EDTA), pink (K2EDTA), or green (lithium heparin).
Specimen Preparation
Allow specimen to clot completely at room temperature. Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.4 mL)
Storage/Transport Temperature
Refrigerated.
Stability (from collection to initiation)
After separation from cells: Ambient: 5 days; Refrigerated: 2 weeks; Frozen: 1 year
Interpretive Data
Interpretive Data: Human chorionic gonadotropin (hCG) is a valuable aid in the management of patients with trophoblastic tumors, nonseminomatous testicular tumors, and seminomas when used in conjunction with information available from the clinical evaluation and other diagnostic procedures. Increased serum hCG concentrations have also been observed in melanoma, carcinomas of the breast, gastrointestinal tract, lung, and ovaries, and in benign conditions, including cirrhosis, duodenal ulcer, and inflammatory bowel disease. This result cannot be interpreted as absolute evidence of the presence or absence of malignant disease. This result is not interpretable as a tumor marker in pregnant females.
The combination of the specific monoclonal antibodies used in the Roche Beta HCG electrochemiluminescent immunoassay recognize the holo-hormone, "nicked" forms of hCG, the beta-core fragment, and the free beta-subunit. Results obtained with different test methods or kits cannot be used interchangeably. Although this assay is FDA cleared for use in the detection of pregnancy, it is not labeled for use as a tumor marker.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Unacceptable Conditions
CSF (refer to Beta-hCG, Quantitative (Tumor Marker) CSF, ARUP test code 0020730). Specimens left to clot at 2-8°C or specimens subjected to repeated freeze/thaw cycles.
